Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aamir Hameed has a total of 125 co-authors. Here are the top co-authors by number of shared publications:

  • Andrew Malone

    Tissue Engineering Research Group (TERG), Department of Anatomy and Regenerative Medicine, Royal College of Surgeons in Ireland - RCSI University of Medicine and Health Sciences, Dublin, Ireland

    5 shared publications
  • Maimoona Azhar

    Graduate Entry Medicine, School of Medicine, RCSI University of Medicine and Health Sciences, Dublin, Ireland

    5 shared publications
  • Faisal H. Cheema

    Tilman J. Fertitta Family College of Medicine, University of Houston, Houston, USA

    4 shared publications
  • Jemil Saidi

    RCSI Univ Med & Hlth Sci, Tissue Engn Res Grp, Dublin, Ireland

    4 shared publications
  • Babar Hasan

    Division of Cardiothoracic Sciences, Sindh Institute of Urology and Transplantation (SIUT), Karachi, Pakistan

    3 shared publications
  • Claire Conway

    School of Medicine, RCSI University of Medicine and Health Sciences, Dublin, Ireland

    3 shared publications

Latest Publications

  • The role of neuromodulation in heart failure with preserved ejection fraction

    by Jumana Algheffari, Abdel Rahman Salameh, Lina Adil, Aamir Hameed, Kurdo Araz


  • Open Access

    Phenotype Characterization of Heart Failure with Preserved Ejection Fraction in Medical Device and Surgical Trials

    by Kurdo Araz, Francesco Fioretti, Sara Ladak, Mohammed Obaidan, Javed Butler, Aamir Hameed

    Aims: Heart failure with preserved ejection fraction (HFpEF) prevalence is nearing 50% of all heart failure cases and is often associated with advanced age, obesity, atrial fibrillation and hypertension, and medical approaches are limited. This review aims to determine the potential of medical devices or surgical interventions in treating HFpEF and to propose specific phenotypes of HFpEF. Methods and Results: A systematic review was conducted using various clinical trial databases and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines followed by descriptive analysis and methodology quality assessment. Inclusion criteria included a medical device or surgical intervention involving HFpEF patients defined by a left ventricular ejection fraction (LVEF) ≥50% and signs of diastolic dysfunction. Twenty-four novel trials were identified involving n = 1752 participants: 17 medical device trials [3 interatrial shunt device trials (n = 1069), 1 atrial flow regulator trial (n = 41), 3 vagal nerve stimulation trials (n = 112), 1 baroreflex activation therapy trial (n = 21), 1 cardiac contractility modulator trial (n = 47), 6 cardiac resynchronization therapy trials (n = 178) and 2 functional electrical stimulation therapy trials (n = 89)] and 7 surgical intervention trials [1 renal denervation trial (n = 25), 3 greater splanchnic nerve ablation trials (n = 111), 2 catheter ablation trials (n = 55) and 1 pericardiotomy procedure trial (n = 4)]. One trial completed phase 3 trials, 20 trials completed phase 1 trials with further trials, and 5 trials completed phase 1 trials without further trials. Conclusions: Overall, 16 out of 24 trials have at least demonstrated safety and feasibility. However, despite many trials of a medical device or surgical procedure showing proof of concept to treat HFpEF phenotypes, they do not provide sufficient evidence of long-term benefit. More robust and phenotype-based clinical trials are needed to ensure evidence-based solutions are developed in HFpEF.


  • Open Access

    Miniature Implantable Left Atrial/Ventricular Pump to Treat Symptoms of Heart Failure With Preserved Ejection Fraction

    by Andrew J. Malone, Kurdo Araz, Jemil Saidi, Donald Hickey, Darragh Colgan, Aamir Hameed


  • Open Access

    Biosensors with left ventricular assist devices

    by Mahmoud Abbassy, Muhammad Zain Ali, Riya Manas Sharma, Yohan Porus Irani, Adil Dahlan, Maimoona Azhar, Nadeem Aslam, Babar Hasan, Aamir Hameed

    Heart failure imposes a significant global health burden, standing as a primary contributor to mortality. Various indicators and physiological shifts within the body may hint at distinct cardiac conditions. Specific biosensors have the capability to identify these changes. Integrating or embedding these biosensors into mechanical circulatory support devices (MCSDs), such as left ventricular assist devices (LVADs), becomes crucial for monitoring alterations in biochemical and physiological factors subsequent to an MCSD implantation. Detecting abnormal changes early in the course of disease progression will allow for improved patient outcomes and prognosis following an MCSD implantation. The aim of this review is to explore the available biosensors that may be coupled or implanted alongside LVADs to monitor biomarkers and changes in physiological parameters. Different fabrication materials for the biosensors are discussed, including their advantages and disadvantages. This review also examines the feasibility of integrating feedback control mechanisms into LVAD systems using data from the biosensors. Challenges facing this emerging technology and future directions for research and development are outlined as well. The overarching goal is to provide an overview of how implanted biosensors may improve the performance and outcomes of LVADs through continuous monitoring and closed-loop control. Graphical Abstract


  • Large animal models to study effectiveness of therapy devices in the treatment of heart failure with preserved ejection fraction (HFpEF)

    by Shane Michael Fisher, Anjali Rosanna Murally, Zahra Rajabally, Talal Almas, Maimoona Azhar, Faisal H. Cheema, Andrew Malone, Babar Hasan, Nadeem Aslam, Jemil Saidi, et al.

    Our understanding of the complex pathophysiology of Heart failure with preserved ejection fraction (HFpEF) is limited by the lack of a robust in vivo model. Existing in-vivo models attempt to reproduce the four main phenotypes of HFpEF; ageing, obesity, diabetes mellitus and hypertension. To date, there is no in vivo model that represents all the haemodynamic characteristics of HFpEF, and only a few have proven to be reliable for the preclinical evaluation of potentially new therapeutic targets. HFpEF accounts for 50% of all the heart failure cases and its incidence is on the rise, posing a huge economic burden on the health system. Patients with HFpEF have limited therapeutic options available. The inadequate effectiveness of current pharmaceutical therapeutics for HFpEF has prompted the development of device-based treatments that target the hemodynamic changes to reduce the symptoms of HFpEF. However, despite the potential of device-based solutions to treat HFpEF, most of these therapies are still in the developmental stage and a relevant HFpEF in vivo model will surely expedite their development process. This review article outlines the major limitations of the current large in-vivo models in use while discussing how these designs have helped in the development of therapy devices for the treatment of HFpEF. Graphical abstract


  • Open Access

    A European update on transcatheter aortic valve implantation (TAVI) in the COVID era

    by Ishan Antony, Hyab Mehari Abraha, Aamir Hameed, Claire Conway

    Minimally invasive approaches for aortic valve replacement are now at the forefront of pathological aortic valve treatment. New trials show comparability of these devices to existing therapies, not only in high‐risk surgical cohorts but also in low‐risk and intermediate‐risk cohorts. This review provides vital clinical and anatomical background to aortic valvular disease treatment guidelines, while also providing an update on transcatheter aortic valve implantation (TAVI) devices in Europe, their interventional trials and associated complications.


  • Open Access

    2D and 3D in-Vitro models for mimicking cardiac physiology

    by Gerges Abdelsayed, Danish Ali, Andrew Malone, Jemil Saidi, Manoj Myneni, Keshava Rajagopal, Faisal H. Cheema, Aamir Hameed


  • Open Access

    In vitro benchtop mock circulatory loop for heart failure with preserved ejection fraction emulation

    by Andrew Malone, Sean Gallagher, Jemil Saidi, Gina Rizq, Enda O’dOwd, Derek Vallence, Aamir Hameed

    In this work, a novel mock circulatory loop (MCL) is presented that is capable of simulating both healthy cardiac function and Heart Failure with preserved Ejection Fraction (HFpEF). This MCL differs from others presented in the literature as it features two independently actuated heart chambers, representing the left atrium and the left ventricle. This is an important improvement over other designs as it allows for potential HFpEF treatments to be examined, not just in relation to their effect on the left ventricle but also on the left atrium. The aim of this work was to show that novel MCL designs could be developed to allow for testing of new mechanical circulatory support devices for the treatment of HFpEF. Two loop configurations are presented, one featuring hard PVC cylindrical chambers and one that features soft silicone chambers which are anatomically analogous to the native heart. We show that both MCLs are capable of simulating the onset of HFpEF with a sustained increase in diastolic pressure of 62.03% and a sustained decrease in end diastolic volume (EDV) of 14.24%.


  • Open Access

    Advancements in left ventricular assist devices to prevent pump thrombosis and blood coagulopathy

    by Grainne Malone, Gerges Abdelsayed, Fianait Bligh, Fatma Al Qattan, Saifullah Syed, Prateepan Varatharajullu, Augustin Msellati, Daniela Mwipatayi, Maimoona Azhar, Andrew Malone, et al.

    Mechanical circulatory support (MCS) devices, such as left ventricular assist devices (LVADs) are very useful in improving outcomes in patients with advanced‐stage heart failure. Despite recent advances in LVAD development, pump thrombosis is one of the most severe adverse events caused by LVADs. The contact of blood with artificial materials of LVAD pumps and cannulas triggers the coagulation cascade. Heat spots, for example, produced by mechanical bearings are often subjected to thrombus build‐up when low‐flow situations impair washout and thus the necessary cooling does not happen. The formation of thrombus in an LVAD may compromise its function, causing a drop in flow and pumping power leading to failure of the LVAD, if left unattended. If a clot becomes dislodged and circulates in the bloodstream, it may disturb the flow or occlude the blood vessels in vital organs and cause internal damage that could be fatal, for example, ischemic stroke. That is why patients with LVADs are on anti‐coagulant medication. However, the anti‐coagulants can cause a set of issues for the patient—an example of gastrointestinal (GI) bleeding is given in illustration. On account of this, these devices are only used as a last resort in clinical practice. It is, therefore, necessary to develop devices with better mechanics of blood flow, performance and hemocompatibility. This paper discusses the development of LVADs through landmark clinical trials in detail and describes the evolution of device design to reduce the risk of pump thrombosis and achieve better hemocompatibility. Whilst driveline infection, right heart failure and arrhythmias have been recognised as LVAD‐related complications, this paper focuses on complications related to pump thrombosis, especially blood coagulopathy in detail and potential strategies to mitigate this complication. Furthermore, it also discusses the LVAD implantation techniques and their anatomical challenges.


  • Open Access

    The role of anti-inflammatory drugs and nanoparticle-based drug delivery models in the management of ischemia-induced heart failure

    by Kathryn E. Haley, Talal Almas, Saeed Shoar, Shan Shaikh, Maimoona Azhar, Faisal Habib Cheema, Aamir Hameed